英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Aristida查看　Aristida　在百度字典中的解释百度英翻中〔查看〕
Aristida查看　Aristida　在Google字典中的解释Google英翻中〔查看〕
Aristida查看　Aristida　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home | Consynance Therapeutics | Rensselaer, NY
    ConSynance Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming breakthrough scientific discoveries into life‐changing therapies for people affected by rare central nervous system (CNS) disorders Our current focus is on neuropsychiatric conditions associated with dysregulation of the neurotransmitters serotonin, dopamine, and norepinephrine We are
  • Items2 - ConSynance
    PIPELINE Developing innovative treatments for rare CNS disorders Our programs target rare CNS and neurodevelopmental disorders through novel mechanisms of action
  • CSTI-500: A Phase 2-Ready, Tunable Triple Monoamine Reuptake Inhibitor
    CSTI-500 is an innovative, orally administered New Chemical Entity (NCE) designed to restore key neurotransmitter balance in Prader-Willi Syndrome (PWS) This Phase 2–ready therapy aims to comprehensively address hyperphagia and other neurobehavioral challenges, offering a promising approach to improve patient outcomes
  • CSTI-100 HBS-102 - ConSynance
    In 2021 ConSynance reached an asset purchase agreement with Harmony Biosciences (HMBY) for an early clinical asset, CSTI-100, now renamed HBS-102 Harmony is currently evaluating the potential of HBS-102, a first-in-class MCHR1 antagonist, in a variety of rare neurological areas Harmony Biosciences holds the full development and commercialization rights globally, with the exception of Greater
  • CSTI-500 - ConSynance
    CSTI-500 is First-in-Class, orally administered New Chemical Entity (NCE), Triple Monoamine Reuptake Inhibitor (TRI) By simultaneously inhibiting the reuptake of serotonin, dopamine, and norepinephrine, CSTI-500 can address the often-reduced levels of these neurotransmitters in PWS patients It is an optimally balanced TRI with unique pharmacological features that allow for predictable and
  • News | Consynance Therapeutics | ConSynance
    ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Trial of CSTI-500 for Prader-Willi Syndrome June 16, 2026 ConSynance Therapeutics today announced that the first participant has been dosed in its Phase 2a clinical trial of CSTI-500 for Prader-Willi syndrome (PWS), marking an important clinical development milestone for the program CSTI-500 is ConSynance’s investigational
  • A New Milestone in Prader-Willi Syndrome Care: FDA Approves VYKAT™ XR . . .
    The FDA approval of VYKAT™ XR opens new doors for the PWS community, underscoring the power of focused research and collaboration At ConSynance Therapeutics, we look forward to advancing CSTI-500 and partnering with patients, families, and healthcare providers in our shared goal to improve outcomes and enhance quality of life for all those affected by PWS
  • CSTI-500 - consynance. com
    Triple Monoamine Reuptake Inhibitor for the treatment of hyperphagia in Prader-Willi Syndrome
  • Blog | ConSynance
    Embracing Hope: Rare Disease Day 2024 and ConSynance Therapeutics' Commitment On this Rare Disease Day, we stand in solidarity with the rare disease community to shine a light on conditions that often go unnoticed





中文字典-英文字典  2005-2009